Health welcomes the first batch of mpox treatment as cases increase
20 June 2024
The Department of Health has received a batch of mpox specific treatment, Tecovirimat (also known as TPOXX or ST-246) for treatment of patients who experience severe health complications as a result of mpox disease.
The process to secure more treatment including vaccine is underway in case the need arises.
However, all mild cases will continue to be managed with supportive treatment used to manage complications like fever, pneumonia and skin infections.
The department urges all people regardless of gender, age, sexual orientation, with suspected mpox symptoms or who had physical contact with known cases to present themselves at the healthcare facility for clinical evaluation because anyone can contract this preventable and treatable disease.